Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
10/13/2017
Trade Name:
Stelara
Generic Name or Proper Name (*):
ustekinumab
Indications Studied:
Psoriasis treatment of adolescent patients ages 12-17 years
Label Changes Summary:
*Safety and effectiveness of have been established in pediatric subjects 12 to 17 years old with moderate to severe plaque psoriasis. Use of in this age group is supported by evidence from a multicenter, randomized, 60-week trial that included a 12-week, double-blind, placebo-controlled, parallel-group portion, in 110 pediatric subjects 12 years and older. *Safety and effectiveness for pediatric patients less than 12 years of age have not been established. *Adverse reactions observed in 12-17 years were similar to adults. *Information on dosing, adverse reactions, and clinical trial. *Postmarketing study
PREA(P):
P
Sponsor:
Janssen
NNPS:
FALSE
Therapeutic Category:
Monoclonal antibody
-
-